Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2013 by Cangene Corporation.
Recruitment status was  Active, not recruiting
Information provided by (Responsible Party):
Cangene Corporation Identifier:
First received: October 7, 2008
Last updated: January 29, 2014
Last verified: June 2013
No Study Results Posted on for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: November 2014
  Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):